KULICKE & SOFFA INDUSTRIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KULICKE & SOFFA INDUSTRIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $654.08M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $706.23M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $742.49M | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | $1.50B | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | $1.52B | Nov 16, 2023 |
| FY2020 | Oct 3, 2020 | $177.69M | Nov 20, 2020 |
| FY2020 | Jun 27, 2020 | $150.45M | Nov 20, 2020 |
| FY2020 | Mar 28, 2020 | $150.74M | Nov 20, 2020 |
| FY2020 | Dec 28, 2019 | $144.30M | Nov 20, 2020 |
| FY2020 | Sep 28, 2019 | $139.83M | Nov 20, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 29, 2018 | $184.82M | Nov 20, 2018 |
| FY2018 | Jun 30, 2018 | $268.83M | Nov 20, 2018 |
| FY2018 | Mar 31, 2018 | $221.77M | Nov 20, 2018 |
| FY2018 | Dec 30, 2017 | $213.69M | Nov 20, 2018 |
| FY2018 | Sep 30, 2017 | $215.89M | Nov 20, 2018 |
| FY2018 | Jul 1, 2017 | $243.90M | Nov 20, 2018 |
| FY2018 | Apr 1, 2017 | $199.61M | Nov 20, 2018 |
| FY2018 | Dec 31, 2016 | $149.64M | Nov 20, 2018 |
| FY2017 | Oct 1, 2016 | $145.84M | May 31, 2018 |
| FY2017 | Jul 2, 2016 | $216.41M | May 31, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $277.92M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $268.75M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $358.66M | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | $748.32M | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | $696.99M | Nov 16, 2023 |
| FY2020 | Oct 3, 2020 | $88.89M | Nov 20, 2020 |
| FY2020 | Jun 27, 2020 | $69.42M | Nov 20, 2020 |
| FY2020 | Mar 28, 2020 | $69.30M | Nov 20, 2020 |
| FY2020 | Dec 28, 2019 | $70.36M | Nov 20, 2020 |
| FY2020 | Sep 28, 2019 | $65.44M | Nov 20, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $213.0K | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | ($69.01M) | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $57.15M | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | $433.55M | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | $367.16M | Nov 16, 2023 |
| FY2020 | Oct 3, 2020 | $15.78M | Nov 20, 2020 |
| FY2020 | Jun 27, 2020 | $11.15M | Nov 20, 2020 |
| FY2020 | Mar 28, 2020 | $11.89M | Nov 20, 2020 |
| FY2020 | Dec 28, 2019 | $13.48M | Nov 20, 2020 |
| FY2020 | Sep 28, 2019 | $6.40M | Nov 20, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | ($3.22M) | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | ($92.50M) | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $39.44M | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | $470.07M | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | $412.45M | Nov 16, 2023 |
| FY2020 | Oct 3, 2020 | $23.05M | Nov 20, 2020 |
| FY2020 | Jun 27, 2020 | $10.97M | Nov 20, 2020 |
| FY2020 | Mar 28, 2020 | $11.08M | Nov 20, 2020 |
| FY2020 | Dec 28, 2019 | $13.41M | Nov 20, 2020 |
| FY2020 | Sep 28, 2019 | $7.69M | Nov 20, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $149.62M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $151.21M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $144.70M | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | $136.85M | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | $137.48M | Nov 16, 2023 |
| FY2022 | Oct 3, 2020 | $123.46M | Aug 8, 2023 |
| FY2021 | Sep 28, 2019 | $116.17M | Nov 18, 2021 |
| FY2020 | Sep 29, 2018 | $119.62M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $100.20M | Nov 15, 2019 |
| FY2018 | Oct 1, 2016 | $92.37M | Nov 20, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $167.70M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $165.56M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $152.98M | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | $140.05M | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | $147.06M | Nov 16, 2023 |
| FY2022 | Oct 3, 2020 | $116.01M | Aug 8, 2023 |
| FY2021 | Sep 28, 2019 | $116.81M | Nov 18, 2021 |
| FY2020 | Sep 29, 2018 | $123.19M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $133.60M | Nov 15, 2019 |
| FY2018 | Oct 1, 2016 | $134.71M | Nov 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $113.57M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $31.04M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $173.40M | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | $390.19M | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | $300.03M | Nov 16, 2023 |
| FY2022 | Oct 3, 2020 | $94.41M | Aug 8, 2023 |
| FY2021 | Sep 28, 2019 | $65.97M | Nov 18, 2021 |
| FY2020 | Sep 29, 2018 | $123.50M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $136.31M | Nov 15, 2019 |
| FY2018 | Oct 1, 2016 | $68.41M | Nov 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $17.20M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $16.15M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $44.41M | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | $22.99M | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | $22.78M | Nov 16, 2023 |
| FY2022 | Oct 3, 2020 | $11.72M | Aug 8, 2023 |
| FY2021 | Sep 28, 2019 | $11.74M | Nov 18, 2021 |
| FY2020 | Sep 29, 2018 | $20.50M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $25.59M | Nov 15, 2019 |
| FY2018 | Oct 1, 2016 | $6.22M | Nov 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $1.10B | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $1.24B | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | $1.50B | Nov 14, 2024 |
| FY2023 | Oct 1, 2022 | $1.59B | Nov 16, 2023 |
| FY2022 | Oct 2, 2021 | $1.60B | Aug 8, 2023 |
| FY2021 | Oct 3, 2020 | $1.05B | Nov 18, 2021 |
| FY2020 | Sep 28, 2019 | $1.08B | Nov 20, 2020 |
| FY2019 | Sep 29, 2018 | $1.19B | Nov 15, 2019 |
| FY2018 | Sep 30, 2017 | $1.17B | Nov 20, 2018 |
| FY2017 | Oct 1, 2016 | $982.44M | May 31, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $282.85M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $296.15M | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | $325.22M | Nov 14, 2024 |
| FY2023 | Oct 1, 2022 | $393.95M | Nov 16, 2023 |
| FY2022 | Oct 2, 2021 | $506.39M | Aug 8, 2023 |
| FY2021 | Oct 3, 2020 | $296.57M | Nov 18, 2021 |
| FY2020 | Sep 28, 2019 | $310.55M | Nov 20, 2020 |
| FY2019 | Sep 29, 2018 | $305.53M | Nov 15, 2019 |
| FY2018 | Sep 30, 2017 | $251.08M | Nov 20, 2018 |
| FY2017 | Oct 1, 2016 | $182.92M | May 31, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $821.49M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $944.01M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $1.17B | Nov 20, 2025 |
| FY2025 | Oct 1, 2022 | $1.19B | Nov 20, 2025 |
| FY2024 | Oct 2, 2021 | $1.10B | Nov 14, 2024 |
| FY2023 | Oct 3, 2020 | $757.99M | Nov 16, 2023 |
| FY2022 | Sep 28, 2019 | $769.06M | Aug 8, 2023 |
| FY2021 | Sep 29, 2018 | $880.21M | Nov 18, 2021 |
| FY2020 | Sep 30, 2017 | $920.03M | Nov 20, 2020 |
| FY2019 | Oct 1, 2016 | $799.52M | Nov 15, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $69.52M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $89.75M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $88.67M | Nov 20, 2025 |
| FY2023 | Oct 1, 2022 | $68.10M | Nov 16, 2023 |
| FY2022 | Oct 2, 2021 | $72.95M | Aug 8, 2023 |
| FY2021 | Oct 3, 2020 | $56.70M | Nov 18, 2021 |
| FY2020 | Sep 28, 2019 | $55.69M | Nov 20, 2020 |
| FY2019 | Sep 29, 2018 | $56.55M | Nov 15, 2019 |
| FY2018 | Sep 30, 2017 | $56.32M | Nov 20, 2018 |
| FY2017 | Oct 1, 2016 | $81.27M | May 31, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $1.20B | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $1.24B | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | $1.36B | Nov 14, 2024 |
| FY2023 | Oct 1, 2022 | $1.34B | Nov 16, 2023 |
| FY2022 | Oct 2, 2021 | $948.55M | Aug 8, 2023 |
| FY2021 | Oct 3, 2020 | $616.12M | Nov 18, 2021 |
| FY2020 | Sep 28, 2019 | $594.63M | Nov 20, 2020 |
| FY2019 | Sep 29, 2018 | $613.53M | Nov 15, 2019 |
| FY2018 | Sep 30, 2017 | $569.08M | Nov 20, 2018 |
| FY2017 | Oct 1, 2016 | $442.98M | May 31, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | $215.71M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | $227.15M | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | $529.40M | Nov 14, 2024 |
| FY2023 | Oct 1, 2022 | $555.54M | Nov 16, 2023 |
| FY2022 | Oct 2, 2021 | $362.79M | Aug 8, 2023 |
| FY2021 | Oct 3, 2020 | $188.13M | Nov 18, 2021 |
| FY2020 | Sep 28, 2019 | $364.18M | Nov 20, 2020 |
| FY2019 | Sep 29, 2018 | $320.63M | Nov 15, 2019 |
| FY2018 | Sep 30, 2017 | $392.41M | Nov 20, 2018 |
| FY2017 | Oct 1, 2016 | $423.91M | May 31, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | 0 | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | (1) | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | 1 | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | 7 | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | 5 | Nov 16, 2023 |
| FY2020 | Oct 3, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Jun 27, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Mar 28, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Dec 28, 2019 | 0 | Nov 20, 2020 |
| FY2020 | Sep 28, 2019 | 0 | Nov 20, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | 0 | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | (1) | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | 0 | Nov 20, 2025 |
| FY2024 | Oct 1, 2022 | 7 | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | 5 | Nov 16, 2023 |
| FY2020 | Oct 3, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Jun 27, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Mar 28, 2020 | 0 | Nov 20, 2020 |
| FY2020 | Dec 28, 2019 | 0 | Nov 20, 2020 |
| FY2020 | Sep 28, 2019 | 0 | Nov 20, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Oct 4, 2025 | 51.92M | Nov 20, 2025 |
| FY2025 | Sep 28, 2024 | 53.85M | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | 56.31M | Nov 14, 2024 |
| FY2023 | Oct 1, 2022 | 57.13M | Nov 16, 2023 |
| FY2022 | Oct 2, 2021 | 61.93M | Aug 8, 2023 |
| FY2021 | Oct 3, 2020 | 61.56M | Nov 18, 2021 |
| FY2020 | Sep 28, 2019 | 63.17M | Nov 20, 2020 |
| FY2019 | Sep 29, 2018 | 67.14M | Nov 15, 2019 |
| FY2018 | Sep 30, 2017 | 70.20M | Nov 20, 2018 |
| FY2017 | Oct 1, 2016 | 70.42M | May 31, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 28, 2024 | $44.16M | Nov 14, 2024 |
| FY2024 | Sep 30, 2023 | $42.04M | Nov 14, 2024 |
| FY2024 | Oct 1, 2022 | $39.36M | Nov 14, 2024 |
| FY2023 | Oct 2, 2021 | $33.45M | Nov 16, 2023 |
| FY2022 | Oct 3, 2020 | $30.23M | Aug 8, 2023 |
| FY2021 | Sep 28, 2019 | $31.57M | Nov 18, 2021 |
| FY2020 | Sep 29, 2018 | $8.18M | Nov 20, 2020 |
| FY2019 | Sep 30, 2017 | $0 | Nov 15, 2019 |
| FY2018 | Oct 1, 2016 | $0 | Nov 20, 2018 |